CEXS-UPF: More than 70% of bladder cancers have mutations in the TERT gene

CEXS-UPF: More than 70% of bladder cancers have mutations in the TERT gene

News from CEXS-UPF

Professor Francisco X. Real, a member of the Department of Experimental Sciences and Health (CEXS-UPF) and head of the group of epithelial carcinogenesis at the National Cancer Research Centre (CNIO), has coordinated a study which has revealed that more than 70% of bladder cancers have somatic mutations in the gene TERT (telomerase reverse transcriptase).

These results, which have just been published in the online edition of the journal European Urology, showed that this gene is the one with a higher frequency of mutations in bladder cancer, a tumor type that is a serious problem public health in Spain, recognized as having the highest incidence rates in the world, with 11,200 new cases each year. The TERT gene is involved in the protection of DNA, processes of cellular aging and cancer.

More information:
UPF press release (in Catalan)

Yves Allory, Willemien Beukers, Ana Sagrera, Marta Flández, Miriam Marqués, Mirari Márquez, Kirstin A. van der Keur, Lars Dyrskjot, Irene Lurkin, Marcel Vermeij, Alfredo Carrato, Josep Lloreta, José A. Lorente, Enrique Carrillo-de Santa Pau, Roy G. Masius, Manolis Kogevinas, Ewout W. Steyerberg, Angela A.G. van Tilborg, Cheno Abas, Torben F. Orntoft, Tahlita C.M. Zuiverloon, Núria Malats, Ellen C. Zwarthoff and Francisco X. Real, (2013), "Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome", European Urology, setembre.